Why Trump's 'Made in America' plan leaves us vulnerable
A generic drug finished in an American factory but dependent on a single overseas supplier for its active ingredient may be less secure than an imported medicine produced at two independent plants with multiple qualified suppliers.
TL;DR
- Domestic production does not inherently guarantee supply security for generic drugs.
- A drug manufactured in the U.S. but dependent on a single overseas supplier for its active ingredient may be less secure than an imported medicine with multiple suppliers.
- President Trump's plan to use tariffs to encourage domestic generic drug production may not achieve its goal of supply security.